SynthesisFrontiers in microbiology2026
Comparative efficacy and safety of vonoprazan-based dual therapy vs. bismuth-based quadruple therapy for
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A systematic search of PubMed/MEDLINE, EMBASE, Web of Science, CINAHL, Google Scholar, and the Cochrane Library was conducted through April 2026 (PROSPERO: CRD420251108849) for randomized controlled trials (RCTs). All comparator arms were restricted to conventional PPI-based BQT. Outcomes included eradication rate, total adverse events (AE), nausea, diarrhea, treatment compliance, and bitter taste. Certainty of evidence was assessed using the GRADE approach and trial sequential analysis. Meta-analysis was performed using R software. Results: From 17,661 screened articles, 15 RCTs comprising 4,410 patients were included. Pooled eradication rates were 86.4% with VA and 85.0% with BQT, with no statistically significant difference (RR 1.03, 95% CI 1.00-1.07; Conclusion: VA dual therapy achieves eradication rates comparable to PPI-based BQT while offering a significantly more favorable tolerability profile, driven by fewer total AEs, less nausea, and less bitter taste. As all included trials were conducted in China, generalizability requires further investigation. These findings support VA dual therapy as a viable alternative for first-line
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.